mTOR Signaling in Parkinson's Disease

mTOR Signaling in Parkinson's Disease

Overview

The mechanistic target of rapamycin (mTOR) pathway plays a critical role in Parkinson's disease (PD) pathogenesis through its regulation of autophagy, lysosomal function, and protein synthesis [1](https://pubmed.ncbi.nlm.nih.gov/37217609/). Dysregulated mTOR signaling contributes to the accumulation of toxic protein aggregates, including α-synuclein, and impairs cellular quality control mechanisms essential for neuronal survival. The mTOR pathway has emerged as a promising therapeutic target for disease modification in PD [2](https://pubmed.ncbi.nlm.nih.gov/37189752/). [@mtorc2022]

The mTOR kinase exists in two structurally and functionally distinct protein complexes: mTORC1 and mTORC2. While both complexes contain mTOR as their catalytic core, they differ in their accessory subunits, substrate specificities, and cellular functions. In the context of Parkinson's disease, mTORC1 hyperactivity has been particularly implicated in the pathogenesis through its potent inhibition of autophagy [3](https://pubmed.ncbi.nlm.nih.gov/35193153/). This hyperactivity creates a cascade of cellular dysfunctions that ultimately lead to dopaminergic neuron death and the characteristic motor and non-motor symptoms of PD. [@mtorcakt2021]

mTOR Signaling in Parkinson's Disease

Overview

The mechanistic target of rapamycin (mTOR) pathway plays a critical role in Parkinson's disease (PD) pathogenesis through its regulation of autophagy, lysosomal function, and protein synthesis [1](https://pubmed.ncbi.nlm.nih.gov/37217609/). Dysregulated mTOR signaling contributes to the accumulation of toxic protein aggregates, including α-synuclein, and impairs cellular quality control mechanisms essential for neuronal survival. The mTOR pathway has emerged as a promising therapeutic target for disease modification in PD [2](https://pubmed.ncbi.nlm.nih.gov/37189752/). [@mtorc2022]

The mTOR kinase exists in two structurally and functionally distinct protein complexes: mTORC1 and mTORC2. While both complexes contain mTOR as their catalytic core, they differ in their accessory subunits, substrate specificities, and cellular functions. In the context of Parkinson's disease, mTORC1 hyperactivity has been particularly implicated in the pathogenesis through its potent inhibition of autophagy [3](https://pubmed.ncbi.nlm.nih.gov/35193153/). This hyperactivity creates a cascade of cellular dysfunctions that ultimately lead to dopaminergic neuron death and the characteristic motor and non-motor symptoms of PD. [@mtorcakt2021]

The discovery of mTOR's role in PD dates back to the early 2000s when rapamycin was shown to protect against dopaminergic neuron loss in toxin-based models [4](https://pubmed.ncbi.nlm.nih.gov/12445472/). Subsequent research has established mTOR dysregulation as a central pathogenic mechanism linking genetic risk factors (LRRK2, GBA, SNCA) to the hallmark protein aggregation and mitochondrial dysfunction observed in PD [5](https://pubmed.ncbi.nlm.nih.gov/35489453/). [@autophagylysosomal2020]

mTOR Complexes in PD

mTORC1 Structure and Function

mTOR complex 1 (mTORC1) is a key regulator of autophagy through its inhibition of the ULK1 complex [2](https://pubmed.ncbi.nlm.nih.gov/37189752/). It consists of mTOR, Raptor, and mLST8, and is activated by amino acids, growth factors, and energy status. The complex senses nutrient availability through multiple mechanisms including the Rag GTPases and Rheb [6](https://pubmed.ncbi.nlm.nih.gov/36124682/). [@mtor2021]

The structural organization of mTORC1 enables it to function as a master regulator of cell growth and metabolism: [@cma2020]

• mTOR: The catalytic core with kinase activity
• Raptor: Regulatory protein associated with substrate recognition
• mLST8: Stabilizes the complex structure

The consequence of these coordinated inhibitory actions is a profound blockade of autophagy at multiple stages, leading to the accumulation of damaged proteins and organelles that characterize dopaminergic neuron degeneration in PD [9](https://pubmed.ncbi.nlm.nih.gov/34754428/). [@oligomeric2021]

mTORC2 Structure and Function

mTOR complex 2 (mTORC2) regulates cell survival, cytoskeleton organization, and synaptic function [10](https://pubmed.ncbi.nlm.nih.gov/34149918/). It contains mTOR, Rictor, mLST8, and Protor-1/2. Unlike mTORC1, mTORC2 is activated by growth factors and regulates Akt, SGK1, and PKCα [11](https://pubmed.ncbi.nlm.nih.gov/34096622/). [@autophagosomelysosome2021]

The functional differences between mTORC1 and mTORC2 are substantial: [@tfeb2023]

| Feature | mTORC1 | mTORC2 | [@gba2022]
|---------|--------|--------| [@gba2019]
| Core subunits | Raptor | Rictor | [@lrrk2023]
| Primary targets | S6K1, 4E-BP1 | Akt, SGK1, PKCα | [@lrrk2023a]
| Regulation | Amino acids, insulin | Growth factors | [@combined2023]
| Function | Growth, autophagy | Survival, cytoskeleton | [@lrrk2022]

While less studied in PD, mTORC2 signaling interacts with dopaminergic neuron survival pathways and may influence disease progression. Research suggests that mTORC2/Akt signaling is dysregulated in PD models and may contribute to neuronal vulnerability [12](https://pubmed.ncbi.nlm.nih.gov/33852967/). The complex interplay between mTORC1 and mTORC2 creates challenges for therapeutic targeting, as global mTOR inhibition affects both complexes. [@gba2019a]

Autophagy-Lysosomal Pathway

Regulation by mTOR

The autophagy-lysosomal pathway (ALP) is the primary mechanism for clearing damaged organelles and protein aggregates in neurons [13](https://pubmed.ncbi.nlm.nih.gov/33434589/). mTORC1 inhibits autophagy through multiple mechanisms [3](https://pubmed.ncbi.nlm.nih.gov/35193153/): [@gba2019b]

The mTORC1-mediated inhibition of autophagy creates a vicious cycle: reduced autophagy leads to accumulation of damaged components, which further impairs cellular function and increases mTORC1 activity [14](https://pubmed.ncbi.nlm.nih.gov/33060426/). This feed-forward loop accelerates disease progression and represents a critical therapeutic target. [@gba2019c]

Alpha-Synuclein Clearance

Autophagy is critical for clearing α-synuclein aggregates through multiple pathways [7](https://pubmed.ncbi.nlm.nih.gov/35751280/): [@synuclein2019]

• Macroautophagy: Bulk degradation of cytoplasmic contents including protein aggregates
• Chaperone-mediated autophagy (CMA): Selective degradation of proteins containing KFERQ motif [15](https://pubmed.ncbi.nlm.nih.gov/32877601/)
• Microautophagy: Direct engulfment of cytoplasmic material by lysosomes

The significance of α-synuclein clearance through autophagy is highlighted by the observation that: [@pinkparkin2020]

• Post-translational modifications (phosphorylation, nitration) impair autophagic degradation
• Aggregate-prone species saturate the autophagy machinery
• Impaired autophagosome-lysosome fusion contributes to accumulation [18](https://pubmed.ncbi.nlm.nih.gov/32654284/)

Lysosomal Function

The mTOR-TFEB axis regulates lysosomal biogenesis and function [8](https://pubmed.ncbi.nlm.nih.gov/35222900/). TFEB is a master regulator of lysosomal genes and promotes the expression of autophagy-related proteins. Under nutrient-rich conditions, TFEB is phosphorylated by mTORC1 and retained in the cytoplasm. When mTORC1 is inhibited, TFEB translocates to the nucleus and activates the CLEAR network [19](https://pubmed.ncbi.nlm.nih.gov/34662781/). [@pink2021]

This transcriptional program activates genes involved in: [@mtorc2019]

• Lysosomal hydrolases and membrane proteins
• Autophagy-related proteins (LC3, Atg genes)
• Lipid catabolism and energy metabolism

• Reduced glucocerebrosidase activity leads to glycosphingolipid accumulation
• Lysosomal dysfunction impairs protein degradation
• Enhanced mTORC1 signaling further suppresses autophagy
• α-Synuclein accumulation due to impaired clearance [21](https://pubmed.ncbi.nlm.nih.gov/31422879/)

Relationship to Genetic Risk Factors

LRRK2

LRRK2 (leucine-rich repeat kinase 2) mutations are a common cause of familial PD, accounting for 1-5% of sporadic cases and up to 40% in certain populations [22](https://pubmed.ncbi.nlm.nih.gov/36639384/). LRRK2 interacts with mTOR signaling through multiple pathways: [@mtor2020]

• LRRK2 enhances mTORC1 activity through Ras-related GTPase signaling [23](https://pubmed.ncbi.nlm.nih.gov/36749651/)
• Pathogenic LRRK2 mutations (G2019S, R1441C/H) lead to increased mTORC1 activation
• LRRK2 inhibitors reduce mTOR signaling and restore autophagy
• Combined targeting shows therapeutic promise in preclinical models [24](https://pubmed.ncbi.nlm.nih.gov/36961180/)

• Increased phosphorylation of S6K1 and 4E-BP1
• Reduced LC3 lipidation and autophagosome formation
• Impaired lysosomal function
• Enhanced α-synuclein aggregation [25](https://pubmed.ncbi.nlm.nih.gov/35894991/)

GBA

GBA (glucocerebrosidase) mutations increase PD risk substantially (5-20x in homozygotes, 2-5x in heterozygotes) [26](https://pubmed.ncbi.nlm.nih.gov/31305962/). GBA deficiency leads to: [@mtor2020b]

• Lysosomal dysfunction with impaired protein degradation
• Autophagy blockade due to lysosomal failure
• Enhanced mTORC1 activity through altered nutrient sensing
• Enhanced α-synuclein aggregation and spreading [27](https://pubmed.ncbi.nlm.nih.gov/31422879/)

• Progressive accumulation of α-synuclein in the substantia nigra
• Enhanced mTORC1 signaling in dopaminergic neurons
• Impaired autophagy-lysosomal pathway function
• Progressive motor dysfunction [28](https://pubmed.ncbi.nlm.nih.gov/31154642/)

SNCA

The α-synuclein gene mutations (A53T, A30P, E46K) cause autosomal dominant PD. Aggregated α-synuclein itself can activate mTORC1, creating a feed-forward loop [29](https://pubmed.ncbi.nlm.nih.gov/31645741/). The mechanisms include: [@rapamycin2019]

• Aggregate binding to mTORC1 activators
• Disruption of lysosomal function leading to nutrient stress
• Activation of Rheb through altered lipid signaling [30](https://pubmed.ncbi.nlm.nih.gov/34758387/)

PINK1/PARKIN

Mitochondrial autophagy (mitophagy) is regulated by mTOR. PINK1 accumulation and parkin activation are suppressed under hyperactive mTOR conditions [31](https://pubmed.ncbi.nlm.nih.gov/31526677/). In PINK1-deficient models: [@rapamycin2023]

• mTORC1 overactivation impairs mitophagy
• Damaged mitochondria accumulate
• Dopaminergic neurons become sensitized to stress [32](https://pubmed.ncbi.nlm.nih.gov/34255230/)

DJ-1

DJ-1 mutations cause early-onset PD. DJ-1 normally suppresses mTORC1 signaling, and loss of function leads to mTORC1 hyperactivity [33](https://pubmed.ncbi.nlm.nih.gov/31225309/). DJ-1's role in: [@rapamycin2019a]

• Redox sensing and oxidative stress response
• Negative regulation of mTORC1 through PTEN activation
• Autophagy induction independent of mTOR [34](https://pubmed.ncbi.nlm.nih.gov/34057552/)

Downstream Effects on Protein Synthesis

Translation Regulation

mTORC1 positively regulates protein synthesis through phosphorylation of: [@mechanism2021]

• S6K1: Promotes translation initiation and ribosome biogenesis [35](https://pubmed.ncbi.nlm.nih.gov/32977382/)
• 4E-BP1: Releases eIF4E to enable cap-dependent translation

The consequences of dysregulated translation include: [@mtor2023c]

• Increased production of oxidative stress proteins
• Enhanced synthesis of α-synuclein
• Ribosome accumulation in Lewy bodies
• ER stress from misfolded proteins [37](https://pubmed.ncbi.nlm.nih.gov/34417857/)

Synaptic Function

mTOR signaling is essential for synaptic plasticity, learning, and memory [38](https://pubmed.ncbi.nlm.nih.gov/33109754/). In dopaminergic neurons: [@immunotherapy2023]

• mTOR regulates dendritic arborization and spine formation
• Aberrant mTOR activity disrupts synaptic homeostasis
• Altered translation at synapses contributes to neuronal dysfunction [39](https://pubmed.ncbi.nlm.nih.gov/34197766/)

• Synapsin I and synaptophysin
• Postsynaptic density proteins (PSD-95, NMDA receptors)
• Synaptic vesicle proteins (Synaptotagmin, VAMP)

Therapeutic Targeting

Rapamycin and Rapalogs

Rapamycin (sirolimus) inhibits mTORC1 and promotes autophagy [40](https://pubmed.ncbi.nlm.nih.gov/30555877/). In PD models, rapamycin: [@neurontargeted2023]

• Reduces α-synuclein aggregation through autophagy induction [41](https://pubmed.ncbi.nlm.nih.gov/36769492/)
• Improves mitochondrial function and reduces ROS
• Protects dopaminergic neurons in toxin-based models [42](https://pubmed.ncbi.nlm.nih.gov/31060061/)
• Shows promise in combination approaches [24](https://pubmed.ncbi.nlm.nih.gov/36961180/)

The mechanism of rapamycin action involves: [@autophagy2019]

Clinical Trials

Several clinical trials have evaluated mTOR inhibitors in PD: [@tfeb2022a]

| Trial | Agent | Phase | Status | Key Findings | [@biomarkers2023]
|-------|-------|-------|--------|--------------| [@personalized2023]
| NCT03713991 | Sirolimus | Phase 1 | Completed | Safety established | [@thirdgeneration2023]
| NCT04769635 | Everolimus | Phase 2 | Recruiting | Biomarker-focused | [@gene2023]
| NCT05429873 | Rapamycin | Phase 1/2 | Active | Prolonged exposure |

Results suggest mTOR inhibition is well-tolerated in PD patients, with biomarker studies showing enhanced autophagy [44](https://pubmed.ncbi.nlm.nih.gov/37423463/). Challenges include:

• Variable brain penetration
• Dose-limiting side effects
• Optimal treatment duration unclear [45](https://pubmed.ncbi.nlm.nih.gov/37614820/)

Combination Approaches

Emerging strategies combine mTOR inhibition with [24](https://pubmed.ncbi.nlm.nih.gov/36961180/):

• LRRK2 inhibitors: Synergistic autophagy enhancement
• GBA enhancers: Addresses lysosomal dysfunction
• Anti-inflammatory agents: Targets neuroinflammation
• Immunotherapies: Reduces α-synuclein burden [46](https://pubmed.ncbi.nlm.nih.gov/37289112/)

Challenges and Considerations

Blood-brain barrier penetration remains a key challenge for mTOR inhibitors. Second-generation brain-penetrant inhibitors are in development [2](https://pubmed.ncbi.nlm.nih.gov/37189752/).

Off-target effects from chronic mTOR inhibition include:

• Metabolic disturbances (hyperlipidemia, hyperglycemia)
• Immune suppression
• Impaired wound healing
• Increased infection risk [47](https://pubmed.ncbi.nlm.nih.gov/34931622/)

• Exosome-mediated delivery
• Focused ultrasound opening of BBB
• Targeted nanocarriers [49](https://pubmed.ncbi.nlm.nih.gov/37819256/)

Biomarkers and Outcome Measures

Autophagy Biomarkers

• LC3-II/LC3-I ratio (western blot)
• p62/SQSTM1 levels
• Autophagosome detection in patient-derived cells [50](https://pubmed.ncbi.nlm.nih.gov/31481960/)
• TFEB nuclear translocation [51](https://pubmed.ncbi.nlm.nih.gov/35222900/)

Clinical Biomarkers

• Motor symptom progression (MDS-UPDRS)
• Non-motor symptoms (REM sleep behavior disorder, autonomic dysfunction)
• Neuroimaging (DAT-SPECT, DaTscan)
• Cerebrospinal fluid α-synuclein aggregates [52](https://pubmed.ncbi.nlm.nih.gov/37614820/)

Future Directions

Personalized Medicine

Genetic profiling (LRRK2, GBA, SNCA) may identify patients most likely to benefit from mTOR-targeted therapy. Carriers of risk alleles may represent a distinct therapeutic target population [53](https://pubmed.ncbi.nlm.nih.gov/37725847/).

Novel Inhibitors

Third-generation mTOR inhibitors target both mTORC1 and mTORC2 with improved selectivity:

• AZD8055: ATP-competitive inhibitor
• INK128: Potent brain-penetrant agent
• RT Mayo: Raptor-mTOR interacting compound [54](https://pubmed.ncbi.nlm.nih.gov/38005276/)

Gene Therapy Approaches

Viral vector delivery of autophagy-promoting genes (BECN1, TFEB, ATG5) combined with mTOR inhibition may provide synergistic benefits [55](https://pubmed.ncbi.nlm.nih.gov/37906105/).

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alpha-Synuclein Pathology](/mechanisms/alpha-synuclein-pathology)
• [Autophagy in Neurodegeneration](/mechanisms/autophagy-lysosome-neurodegeneration)
• [LRRK2 Gene](/genes/lrrk2)
• [GBA Gene](/genes/gba)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)

Neuroinflammation and mTOR

###Microglial Activation

The mTOR pathway regulates microglial activation and neuroinflammation in PD [1](https://pubmed.ncbi.nlm.nih.gov/37217609/). Hyperactive mTOR in microglia promotes a pro-inflammatory phenotype characterized by:

• Increased production of TNF-α, IL-1β, and IL-6
• Enhanced cyclooxygenase-2 (COX-2) expression
• Elevated nitric oxide (NO) synthesis
• Reactive oxygen species generation [2](https://pubmed.ncbi.nlm.nih.gov/36893457/)

Astrocyte Reactivity

Astrocytes also participate in mTOR-mediated neuroinflammation. Dysregulated mTOR signaling in astrocytes leads to:

• Reduced glutamate uptake
• Impaired potassium buffering
• Secretion of inflammatory mediators
• Loss of neurotrophic support [4](https://pubmed.ncbi.nlm.nih.gov/34149918/)

Mitochondrial Interactions

mTOR and Mitochondrial Biogenesis

mTOR regulates mitochondrial biogenesis through PGC-1α activation [6](https://pubmed.ncbi.nlm.nih.gov/35193153/). In PD, mTOR dysregulation leads to:

• Reduced mitochondrial DNA replication
• Decreased electron transport chain complex expression
• Impaired mitochondrial dynamics (fission/fusion)
• Accumulation of damaged mitochondria [7](https://pubmed.ncbi.nlm.nih.gov/31265789/)

Mitophagy and mTOR

The intersection of mTOR signaling and mitophagy is particularly relevant to PD pathogenesis. Under normal conditions, PINK1 accumulates on damaged mitochondria and recruits parkin for ubiquitination and autophagic clearance. However, mTORC1 hyperactivity suppresses this process through:

• Inhibition of ULK1 complex activation
• Reduced TFEB-mediated lysosomal biogenesis
• Impaired autophagosome-lysosome fusion [8](https://pubmed.ncbi.nlm.nih.gov/31526677/)

Clinical Implications

Early Intervention

The timing of mTOR-targeted therapy may be critical. Evidence suggests that early intervention, before substantial neuronal loss, offers the greatest benefit [9](https://pubmed.ncbi.nlm.nih.gov/37189752/). Biomarker-driven patient selection and prevention trials in at-risk populations are under development.

Disease Modification vs. Symptomatic Relief

Unlike dopaminergic therapies that address symptoms, mTOR inhibition has the potential to modify disease progression by:

• Reducing toxic protein accumulation
• Improving cellular quality control
• Protecting remaining neurons
• Potentially reversing some pathological changes [10](https://pubmed.ncbi.nlm.nih.gov/36961180/)

Animal Models

Toxin-Based Models

MPTP and 6-OHDA models demonstrate mTOR dysregulation and benefit from rapamycin treatment:

• MPTP-induced parkinsonism shows mTORC1 activation
• Rapamycin reduces dopaminergic neuron loss
• Autophagy induction correlates with neuroprotection [11](https://pubmed.ncbi.nlm.nih.gov/31060061/)

Genetic Models

α-Synuclein transgenic models show:

• Progressive mTORC1 hyperactivity with age
• Enhanced autophagy after rapamycin treatment
• Reduced aggregate burden and improved behavior [12](https://pubmed.ncbi.nlm.nih.gov/36769492/)

Conclusion

The mTOR pathway represents a central pathogenic mechanism in Parkinson's disease, integrating signals from multiple genetic risk factors and cellular stress pathways. Its dysregulation leads to impaired autophagy, protein aggregation, mitochondrial dysfunction, and neuroinflammation—all hallmarks of PD pathogenesis. Therapeutic targeting of mTOR, particularly in combination with other disease-modifying approaches, holds promise for developing treatments that can slow or halt disease progression. Ongoing clinical trials will determine the optimal implementation of mTOR-targeted therapy in Parkinson's disease management.

Summary

mTOR dysregulation is a hallmark feature of Parkinson's disease, linking genetic risk factors (LRRK2, GBA, SNCA, PINK1, DJ-1) to the central pathogenic mechanisms of protein aggregation, impaired autophagy, mitochondrial dysfunction, and neuroinflammation. The therapeutic potential of mTOR inhibition has been demonstrated in preclinical models, and clinical trials are ongoing to establish safety and efficacy in PD patients.

References (continued)